Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-051 pediatric pembrolizumab study in PD-L1-positive advanced melanoma, solid tumors, or lymphoma
MOH_2017-06-13_000515Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in melanoma, Nonhematologic neoplasms and lymphoma, sponsored by Merck & Co. Primary endpoints: Safety and tolerability, Maximum tolerated dose / highest safe dose and 1 more. Started Jun 2015; status: recruiting.
02
Drugs
03
Conditions
melanomaNonhematologic neoplasmslymphoma
Beyond the preview
Go deeper on MOH_2017-06-13_000515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-13_000515.